Gain Therapeutics Past Earnings Performance
Past criteria checks 0/6
Gain Therapeutics's earnings have been declining at an average annual rate of -34.1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 1.6% per year.
Key information
-34.1%
Earnings growth rate
-4.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 1.6% |
| Return on equity | -239.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
May 29Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential
Jan 12Gain Therapeutics appoints CEO
Sep 20Gain Therapeutics: Shares Of Enzyme Therapy/Neurodegeneration Specialist Look Like A Surprisingly Good Value
Oct 27Gain Therapeutics: A True Revolution In Drug Development At Venture-Like Pricing
Aug 19Gain Therapeutics EPS misses by $0.29
May 10Revenue & Expenses Breakdown
How Gain Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -21 | 10 | 3 |
| 30 Jun 24 | 0 | -22 | 10 | 0 |
| 31 Mar 24 | 0 | -21 | 10 | 0 |
| 31 Dec 23 | 0 | -22 | 11 | 0 |
| 30 Sep 23 | 0 | -22 | 11 | 6 |
| 30 Jun 23 | 0 | -22 | 12 | 6 |
| 31 Mar 23 | 0 | -19 | 10 | 0 |
| 31 Dec 22 | 0 | -18 | 10 | 0 |
| 30 Sep 22 | 0 | -16 | 9 | 0 |
| 30 Jun 22 | 0 | -16 | 8 | 0 |
| 31 Mar 22 | 0 | -15 | 8 | 0 |
| 31 Dec 21 | 0 | -14 | 7 | 0 |
| 30 Sep 21 | 0 | -12 | 6 | 0 |
| 30 Jun 21 | 0 | -8 | 4 | 0 |
| 31 Mar 21 | 0 | -5 | 2 | 0 |
| 31 Dec 20 | 0 | -4 | 1 | 0 |
| 30 Sep 20 | 0 | -3 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 2 |
Quality Earnings: GANX is currently unprofitable.
Growing Profit Margin: GANX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GANX is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.
Accelerating Growth: Unable to compare GANX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GANX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GANX has a negative Return on Equity (-239.83%), as it is currently unprofitable.